The Strategy of mTORC1 Inhibition Fails a Phase III Trial

The worst possible outcome when developing a clinical therapy is not an early failure. It is a late failure, in the final and most expensive phase III clinical trial, in which the therapy interacts with a sizable patient population, and after a great deal of time and funding have been devoted to the program. This result is far more likely for therapies based on mechanisms that have smaller rather than larger effect sizes, and where that smaller effect size varies from individual to individual for reasons that are not well understood – something that describes all too much of the past few decades of efforts to treat age-related disease. Unfortunately this worst case phase III failure just happened to resTORbio’s mTORC1 inhibitor RTB101, in tests of its

From http://besthealthnews.com/2019/11/the-strategy-of-mtorc1-inhibition-fails-a-phase-iii-trial/?utm_source=rss&utm_medium=rss&utm_campaign=the-strategy-of-mtorc1-inhibition-fails-a-phase-iii-trial

from
https://healthnews010.wordpress.com/2019/11/19/the-strategy-of-mtorc1-inhibition-fails-a-phase-iii-trial/

From https://jamesjohnson10.blogspot.com/2019/11/the-strategy-of-mtorc1-inhibition-fails.html

from
https://jamesjohnson10.wordpress.com/2019/11/19/the-strategy-of-mtorc1-inhibition-fails-a-phase-iii-trial/